Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055781 · ClinicalTrials.gov registry record · Phase 3
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
A Phase 3 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
NCT02055781: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.
NCT02055781 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 311 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02055781, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
Study Summary
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
Primary Outcome
Proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT).
Interventions
- DRUG Pacritinib
- DRUG Best Available Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Why NCT02055781 stopped before completion
NCT02055781 is an interventional study that assigns participants to a tested intervention. The registered 311 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Pacritinib is the first listed.
NCT02055781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02055781 about?
NCT02055781 is a clinical study titled "Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia". Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
What is the current status of trial NCT02055781?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2014-02. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02055781?
The interventions under investigation include: Pacritinib (DRUG), Best Available Therapy (DRUG).
Who is sponsoring clinical trial NCT02055781?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02055781's enrollment target sits among peer trials
311 1106th of 2000 higher than 894 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia